ESTRO 2024 - Abstract Book

S2130

Clinical - Upper GI

ESTRO 2024

Results:

From July 2021 to January 2023, 15 advanced HCC patients participated in the study. MVI was confirmed radiologically in all cases, with tumour invasion into the main portal vein in 4 patients and into the inferior vena cava in one patient. DLT evaluations were carried out for 3 patients in both cohorts as planned with no DLT incidents reported. Treatment-related serious adverse events were observed in 0 patients in Cohort A and 4 patients (26.7%) in Cohort B. In Cohort B, the median PFS was 2.79 months (95%CI, 1.12 – 6.64). The 6- and 12-month PFS rate stood at 38.1% and 12.7%, respectively, the median OS was not yet determined, and the 6- and 12-month survival rate was 87.5% and 87.5%, respectively.

Conclusion:

The safety of durvalumab and tremelimumab in combination with particle therapy has been confirmed in advanced HCC with MVI, with no elevated SAE incidence compared to reports without particle therapy. While radiotherapy is absent in treatment algorithms in multiple regions, this combination, especially the irradiation of tumours with MVI using C-ion RT, holds promise in managing prognostic determinant tumours and potentially enhancing OS.

Keywords: HCC, particle therapy, Phase Ib

References:

Ogasawara S, Koroki K, Makishima H, et al. Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial. Journal of Clinical Oncology. 2022;40(4_suppl):TPS495-TPS.

115

Digital Poster

The Nutritional Status Effect: Neoadjuvant chemoradiation toxicity in oesophageal cancer

Karun Kamboj 1 , Abiramasundari V 1 , Dayanad Sharma 2 , Supriya Mallick 1 , Aman Sharma 1 , Yousra Izzuddeen KN 1 , Surendra Kumar Saini 2 , Namrata Das 1 , Adrija Ghosh 1 , Naveen Kumar 3 , Akash Jha 4 , Hari Sagiraju 5 , Tarun Kumar 6 1 National Cancer Institute, AIIMS, Radiation Oncology, New Delhi, India. 2 All Indian Institute of Medical Sciences, Radiation Oncology, New Delhi, India. 3 National Cancer Institute, AIIMS, Surgical Oncology, New Delhi, India. 4 National Cancer Institute, AIIMS, Medical Oncology, New Delhi, India. 5 National Cancer Institute, AIIMS, Preventive Oncology, New Delhi, India. 6 University College London, Radiation Oncology, London, United Kingdom

Purpose/Objective: